Evolent Health Inc Class A (EVH)

Evolent Health's stock price has experienced a significant decline over the past six months. Key events impacting the stock price include mixed Q3 2025 earnings, the strategic divestiture of Evolent Care Partners, Q4 2025 and Full Year 2025 results, a convertible senior notes offering, and analyst price target adjustments.

Evolent Health experiences some seasonality in its financial performance, with the fourth quarter tending to be better from an expense standpoint due to holidays and fewer claims. Rising medical costs and expanding demand for value-based care tools also drive demand for Evolent's solutions.

Evolent Health, Inc. specializes in value-based care solutions, aiming to improve health outcomes and reduce costs for individuals with complex conditions. The company operates within the Healthcare sector, offering specialty care management, an integrated value-based care platform, administrative services, Identifi, and Machinify Auth Intelligence.

Evolent Health is headquartered in Arlington, Virginia, and manages care in all 50 states across the United States. The company has a global workforce with employees in the U.S., India, and the Philippines and is exploring geographic diversification with pilots targeting the United Kingdom and select Middle Eastern markets.

Evolent Health maintains a positive brand reputation, consistently recognized as a top place to work in healthcare nationally. Positive events contributing to its reputation include the appointment of Archie Mayani as Chief Product Officer, a partnership with American Oncology Network, and a focus on value-based specialty care and rebranding.

Evolent Health, Inc.'s ownership is predominantly held by institutional investors, with institutional ownership exceeding 96%. Insider ownership has seen a slight increase, reaching 2.68% by June 2025.